{"id":"NCT04315298","sponsor":"Regeneron Pharmaceuticals","briefTitle":"Evaluation of the Efficacy and Safety of Sarilumab in Hospitalized Patients With COVID-19","officialTitle":"An Adaptive Phase 2/3, Randomized, Double-Blind, Placebo-Controlled Study Assessing Efficacy and Safety of Sarilumab for Hospitalized Patients With COVID-19","status":"COMPLETED","phase":"PHASE2","dates":{"start":"2020-03-18","primaryCompletion":"2020-07-24","completion":"2020-09-02","firstPosted":"2020-03-19","resultsPosted":"2021-09-23","lastUpdate":"2021-09-23"},"enrollment":1912,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["COVID-19"],"interventions":[{"type":"DRUG","name":"Sarilumab","otherNames":["KevzaraÂ®","REGN88","SAR153191"]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Sarilumab 200mg IV (P2)","type":"EXPERIMENTAL"},{"label":"Sarilumab 200mg IV (P3:C1)","type":"EXPERIMENTAL"},{"label":"Sarilumab 400mg IV (P2)","type":"EXPERIMENTAL"},{"label":"Sarilumab 400mg IV (P3:C1)","type":"EXPERIMENTAL"},{"label":"Sarilumab 800mg IV (P3:C2)","type":"EXPERIMENTAL"},{"label":"Sarilumab 800mg IV (P3: C3)","type":"EXPERIMENTAL"}],"summary":"Phase 2:\n\nThe primary objective of the study is to evaluate the clinical efficacy of sarilumab relative to the control arm in adult patients hospitalized with COVID-19 regardless of disease severity strata.\n\nPhase 3 Cohort 1:\n\nThe primary objective of the study is to evaluate the clinical efficacy of sarilumab relative to the control arm in adult patients hospitalized with critical COVID-19 receiving mechanical ventilation at baseline.\n\nPhase 3 Cohort 2:\n\nThe primary objective of the study is to evaluate the clinical efficacy of sarilumab relative to the control arm in adult patients hospitalized with COVID-19 receiving mechanical ventilation at baseline.","primaryOutcome":{"measure":"Percent Change From Baseline in CRP Levels at Day 4 in Participants With Serum IL-6 Level Greater Than the ULN (Phase 2)","timeFrame":"Baseline and Day 4","effectByArm":[{"arm":"Phase 2: Placebo","deltaMin":-0.2,"sd":0.077},{"arm":"Phase 2: Sarilumab 200mg IV","deltaMin":-0.77,"sd":0.018},{"arm":"Phase 2: Sarilumab 400mg IV","deltaMin":-0.78,"sd":0.017}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.0001"},{"comp":"OG000 vs OG002","p":"<0.0001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":14,"exclusionCount":13},"locations":{"siteCount":62,"countries":["United States"]},"refs":{"pmids":["36494054","35219277","34496013"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":39,"n":90},"commonTop":["Alanine aminotransferase increased","Aspartate aminotransferase increased","Transaminases increased","Staphylococcal infection","Pneumonia"]}}